Literature DB >> 6093460

Epidemiology of gestational trophoblastic neoplasm at the Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

M F Aziz, N Kampono, E M Moegni, S Sjamsuddin, B Barnas, R S Samil.   

Abstract

This retrospective research was conducted in the Department of Obstetrics and Gynaecology of the Dr. Cipto Mangunkusumo Hospital, Jakarta, covering the period between 1977 and 1981. The incidence of hydatidiform mole was 1 in 77 pregnancies. The incidence of malignant trophoblastic disease was 1 in 185 pregnancies. Of the 406 cases of hydatidiform mole, 22.9% became malignant. Patients of 24 years of age or younger had a higher risk of getting hydatidiform mole (P less than 0.05) compared to older patients. The risk of becoming malignant increased with age and became evident after 40 years of age. Parity 1 or less was associated with a higher risk of getting hydatidiform mole (P less than 0.05), but had no influence on hydatidiform mole becoming malignant. The influence of blood group was not so clear, although there was a tendency for moles to occur more frequently in patients with blood groups A or B. By contrast, there was a tendency for the change into malignancy to occur more frequently in women with blood groups B or O. Gestational age had no influence towards the change into malignancy or metastasis. Uterine size (greater than 20 weeks gestation) correlated with the progression of hydatidiform mole into malignancy. However, subsequent metastasis was not influenced by the size of the uterus. It was found that 76.4% of malignant trophoblastic diseases originated from hydatidiform moles, 12.4% from abortions, 9.5% from normal deliveries, and 1.2% from ectopic pregnancies. Non-hydatidiform moles had a slightly greater risk for metastasis, although this was not significant. Hydatidiform mole in histologic stages II or III (Hertig-Mansell classification) had a significantly greater tendency (P less than 0.05) to become malignant than in stage I.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093460     DOI: 10.1007/978-1-4684-4811-5_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

Review 1.  Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.

Authors:  Qiuyi Wang; Jing Fu; Lina Hu; Fang Fang; Lingxia Xie; Hengxi Chen; Fan He; Taixiang Wu; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11

2.  Gestational Trophoblastic Disease - Clinicopathological Study at Tertiary Care Hospital.

Authors:  Sunil Vitthalrao Jagtap; Vidhya Aher; Suchi Gadhiya; Swati Sunil Jagtap
Journal:  J Clin Diagn Res       Date:  2017-08-01

3.  Incidence of gestational trophoblastic disease in South Korea: a longitudinal, population-based study.

Authors:  Jin-Sung Yuk; Jong Chul Baek; Ji Eun Park; Hyen Chul Jo; Ji Kwon Park; In Ae Cho
Journal:  PeerJ       Date:  2019-02-20       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.